Coffee Dosage & Pharmacokinetic Health Curve Explorer

Evidence-grounded 24-hour plasma clearance dynamics & epidemiological relative-risk sweet spots

CYP1A2: Standard (t½ = 5.0h) EFSA Cap: 400 mg
Total Daily Intake
225 mg
~2.4 std cups (95mg/cup)
Peak Concentration
3.12 mg/L
Peak at 14:15 (~142 mg circ)
Bedtime Residual (23:00)
38.4 mg
Mild Sleep Latency Delay
Mortality Relative Risk
0.85 RR
15% Risk Reduction (Sweet Spot)
Clinical & Metabolic Archetypes:
24-Hour Pharmacokinetics (Bateman Clearance) ka = 1.5 h⁻¹ | Vd = 0.65 L/kg
Instantaneous Time Inspector 14:00
Circulating: 140.2 mg Plasma: 3.08 mg/L Sleep Pressure Impact: Normal Daytime
Daily Intake Schedule 2 beverages logged
Epidemiological Dose-Response (Poole/Grosso Meta-Analyses) Sweet Spot Zone
0 mg (Clean) 25 mg (Mild) 50 mg (Disrupted) 100+ mg (Severe)
Model: 1-Compartment Bateman GI Absorption ($k_a = 1.5\text{ h}^{-1}$) & Pooled BMJ/Annu Rev Nutr Meta-Analytic RR Curves.
Scientific sources: Poole et al. BMJ 2017;359:j5024; Grosso et al. Annu Rev Nutr 2017;37:131–156; EFSA Scientific Opinion on Caffeine Safety (2015).
Enjoy this tool? Build your own with Super